Get the Stockscreener App
246.78
1.52%
3.6423
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $246.78, with a volume of 4.47M.
It is up +1.52% in the last 24 hours and up +15.82% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$243.14
Open:
$245.255
24h Volume:
4.47M
Relative Volume:
0.73
Market Cap:
$436.04B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
121.72
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+14.02%
1M Performance:
+15.82%
6M Performance:
+7.33%
1Y Performance:
+32.15%
1-Day Range:
$245.20
$249.59
1-Week Range:
$221.94
$249.59
52-Week Range:
$181.73
$249.59
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
246.80 | 415.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,204.62 | 996.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.64 | 580.14B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
127.66 | 297.86B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.51 | 292.17B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie stock hits all-time high at 245.26 USD By Investing.com - Investing.com Canada
AbbVie to Host Second-Quarter 2026 Earnings Conference Call - Investing News Network
Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value? - The Motley Fool
Rx Rundown: Merck KGaA, AbbVie, Sangamo Therapeutics and more - Medical Marketing and Media
AbbVie, Inc. CDR (CAD Hedged) Actuals & Estimates (DUS:4AB0) - TradingView
Will AbbVie's (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix? - Yahoo Finance
Enterprise value to EBITDA forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
A Look at AbbVie Inc (ABBV) After 3.5% Gain -- GF Value $211.36 vs Price $243.14 - GuruFocus
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Price to book forward of AbbVie, Inc. – TURQUOISE:4ABD - TradingView
Enterprise value to EBIT forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie Inc Stock (ABBV) Moved Up by 3.22% on Jun 25: Drivers Behind the Movement - TradingKey
Is AbbVie a Buy After Its Purchase of Apogee? - AOL.com
AbbVie to acquire Apogee Therapeutics in $10.9 billion immunology deal - DOTmed
Pharma Pulse: UPS's Cold Chain Buildout and AbbVie's $10.9B Immunology Bet - Pharmaceutical Commerce
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook - Yahoo Finance
The Number That Could Test AbbVie Stock - Trefis
AbbVie's Big Immunology Acquisition - Forbes
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years - Benzinga
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis - Zacks Investment Research
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $260 to $298 - Moomoo
AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal - Yahoo Finance
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition - Investing.com
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition By Investing.com - Investing.com Canada
PRESCRIPTION DRUGS—W.D. Wash.: Novartis, AbbVie, PhRMA denied preliminary relief in challenge to Washington State 340B delivery law - VitalLaw.com
Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share - Stock Titan
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors. - Yahoo Finance
ABBV Reiterated by Piper Sandler -- Price Target Maintained at $298 - GuruFocus
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - Benzinga
AbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds - PR Newswire
CCORF Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $273 - Moomoo
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout - Yahoo Finance
Abbvie stock holds at Market Perform as Bernstein eyes Apogee deal - Investing.com Canada
ABBV Introduces Boey for Glabellar Lines Following Health Canada Approval - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $234 to $298 - Moomoo
AbbVie receives European approval for age three patients - grafa.com
Years of Rewards: $61 Bil From AbbVie Stock - Trefis
Canaccord raises Abbvie stock price target on acquisition potential - Investing.com
AbbVie (ABBV) Pursues Acquisition of Apogee Therapeutics - GuruFocus
AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV) - Yahoo Finance
Canaccord raises Abbvie stock price target on acquisition potential By Investing.com - Investing.com Canada
Should You Buy Or Sell AbbVie Stock At $230? - Yahoo Finance
Possible Bearish Signals With AbbVie Insiders Disposing Stock - Moomoo
AbbVie Stock Rose 6% After Its $11 Billion Apogee Deal: What a $347 Target Means for Investors - TIKR.com
Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com
Canada clears Boey, a fast-acting neurotoxin that fades in 2-3 weeks - Stock Titan
AbbVie receives European approval for age six patients - grafa.com
AbbVie (ABBV) Gains European Approval for Skyrizi in Younger Pat - GuruFocus
ABBV Receives EU Approval for Maviret Treatment - GuruFocus
AbbVie (ABBV) Secures EU Approval for Skyrizi in Pediatric Psori - GuruFocus
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):